Researchers released new clinical guidelines for treating restless legs syndrome (RLS), emphasizing patient-centered care and ...

Drug therapy: A new study, recently published ... medication Mounjaro and weight loss treatment Zepbound – helps reduce ...

Actual results (including the actual future impact of the initiatives and corporate achievements described herein on Vivos’ future revenues and results of operations and the anticipated benefits of ...

"I'm using [Ozempic] off-label for a whole host of conditions — and have been for years," Dr. Caroline Messer, an ...

Vivos' cost-cutting initiatives also led to a $1 million or 27% year-over-year reduction in operating loss, versus the third quarter of 2023. For the nine months ended September 30, 2024 operating ...

A new study has found that older adults, who are excessively sleepy during the day or have prominent sleep issues, are at an ...

A key player in the market, Apnea Sciences Corporation contributes to innovative solutions that address the diverse causes of snoring. Its commitment to research and development positions it as a ...

Bryan Vadney, an Army Veteran used to love life, being active, spending time with family and friends and taking part in his ...

The aura6000 is an implantable hypoglossal neurostimulator intended to treat adult patients with moderate to severe obstructive sleep apnea. In the OSPREY study ... market-moving breaking financial ...

LivaNova PLC , a market-leading medical technology company, today announced that it met the primary endpoints for its OSPREY randomized controlled trial (RCT), Treating Obstructive Sleep Apnea Using ...

Oct. 31, 2024 — Sleep apnea, a common yet underdiagnosed ... and Parkinson's disease but studies on long-term treatments are lacking. A new study highlights ...